Campbell & CO Investment Adviser LLC Makes New $434,000 Investment in Evolus, Inc. $EOLS

Campbell & CO Investment Adviser LLC acquired a new stake in Evolus, Inc. (NASDAQ:EOLS) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 47,157 shares of the company’s stock, valued at approximately $434,000. Campbell & CO Investment Adviser LLC owned 0.07% of Evolus as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Versor Investments LP acquired a new stake in Evolus in the 2nd quarter worth about $102,000. Pinnacle Associates Ltd. purchased a new stake in Evolus in the second quarter valued at approximately $6,318,000. Y Intercept Hong Kong Ltd increased its position in Evolus by 594.5% during the second quarter. Y Intercept Hong Kong Ltd now owns 259,487 shares of the company’s stock worth $2,390,000 after purchasing an additional 222,126 shares during the last quarter. AlphaQuest LLC raised its stake in Evolus by 229.7% during the second quarter. AlphaQuest LLC now owns 10,706 shares of the company’s stock worth $99,000 after purchasing an additional 7,459 shares during the period. Finally, Bender Robert & Associates acquired a new position in shares of Evolus in the 2nd quarter valued at $231,000. 90.69% of the stock is currently owned by hedge funds and other institutional investors.

Evolus Stock Down 2.0%

EOLS opened at $7.22 on Monday. The firm has a market capitalization of $468.00 million, a P/E ratio of -7.85 and a beta of 0.97. The firm’s 50 day moving average is $6.63 and its 200-day moving average is $8.19. Evolus, Inc. has a 52-week low of $5.71 and a 52-week high of $17.12.

Evolus (NASDAQ:EOLS) last announced its earnings results on Wednesday, November 5th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.05. Evolus had a negative net margin of 20.49% and a negative return on equity of 759.04%. The business had revenue of $68.97 million during the quarter, compared to the consensus estimate of $91.23 million. Evolus has set its FY 2025 guidance at EPS. Equities analysts expect that Evolus, Inc. will post -0.61 earnings per share for the current fiscal year.

Insider Activity

In related news, CMO Tomoko Yamagishi-Dressler sold 5,722 shares of the business’s stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $7.51, for a total value of $42,972.22. Following the transaction, the chief marketing officer owned 89,949 shares in the company, valued at approximately $675,516.99. The trade was a 5.98% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 6.10% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently commented on EOLS shares. Weiss Ratings restated a “sell (e+)” rating on shares of Evolus in a report on Tuesday, November 11th. HC Wainwright lowered their price target on Evolus from $27.00 to $20.00 and set a “buy” rating for the company in a research report on Wednesday, August 6th. Needham & Company LLC restated a “hold” rating and set a $22.00 price target on shares of Evolus in a research note on Wednesday, August 6th. BTIG Research restated a “buy” rating and issued a $18.00 price objective on shares of Evolus in a report on Monday, September 8th. Finally, Wall Street Zen raised Evolus from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Evolus presently has an average rating of “Hold” and an average target price of $21.25.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.